Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes

• Published in: Clinical cancer research Vol. 29; no. 23; pp. 4844 - 4852
• Main Authors: Denu, Ryan A., Yang, Richard K., Lazar, Alexander J., Patel, Shalin S., Lewis, Valerae O., Roszik, Jason, Livingston, J. Andrew, Wang, Wei-Lien, Shaw, Kenna R., Ratan, Ravin, Zarzour, Maria A., Bird, Justin, Raza, Shaan, Akdemir, Kadir C., Rodon Ahnert, Jordi, Subbiah, Vivek, Patel, Shreyaskumar, Conley, Anthony P.
• Format: Journal Article
• Language: English
• Published: United States 01.12.2023
• Subjects: Adult; Bone and Bones - pathology; Bone Neoplasms - genetics; Bone Neoplasms - pathology; Chondrosarcoma - genetics; Chondrosarcoma - pathology; Genomics; Humans; Isocitrate Dehydrogenase - genetics; Isocitrate Dehydrogenase - metabolism; Mutation; Tumor Suppressor Protein p53 - genetics

Chondrosarcomas are the most common primary bone tumor in adults. Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are prevalent. We aimed to assess the clinico-genomic properties of IDH mutant versus IDH wild-type (WT) chondrosarcomas as well as alterations in other genes. We included 93 patien...